Positive phase II data with head and neck, if that's the first trial to be completed. This stock is manipulated with every good spit of news. However, positive AMD data MIGHT generate a small bump and steady re-rate. But with actual trials so far away, it would take something really significant for a genuine re-rate in my opinion.
